Evidence map›Paper›PMID 34215998›Full record

ArticleDrug delivery and translational research2021

Microfluidic systems to study tissue barriers to immunotherapy.

Ann Ramirez, Mayowa Amosu, Priscilla Lee, Katharina Maisel

Abstract read
In one paragraph

Article in Drug delivery and translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Overcoming transport barrier to immunotherapies.Drug delivery and translational research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ann RamirezDepartment of Bioengineering, University of Maryland, College Park, MD, USA.
Mayowa AmosuDepartment of Bioengineering, University of Maryland, College Park, MD, USA.
Priscilla LeeDepartment of Bioengineering, University of Maryland, College Park, MD, USA.
Katharina MaiselDepartment of Bioengineering, University of Maryland, College Park, MD, USA. maiselka@umd.edu.ORCID http://orcid.org/0000-0002-3560-9751

Funding

Regulation and modeling of transport across tissue barriersR35GM142835 · NIGMS · UNIV OF MARYLAND, COLLEGE PARK · PI MAISEL, KATHARINA · 2021 to 2025
$2.0M
Training Program in Cell & Molecular BiologyT32GM080201 · NIGMS · UNIV OF MARYLAND, COLLEGE PARK · PI DELWICHE, CHARLES F · 2009 to 2019
$1.6M
NIGMS NIH HHS R35 GM142835NIGMS NIH HHS T32 GM080201
6 · The paper itself

Abstract

Immunotherapies have been heavily explored in the last decade, ranging from new treatments for cancer to allergic diseases. These therapies target the immune system, a complex organ system consisting of tissues with intricate structures and cells with a multitude of functions. To better understand immune functions and develop better therapeutics, many cellular and 2-dimensional (2D) tissue models have been developed. However, research has demonstrated that the 3-dimensional (3D) tissue structure can significantly affect cellular functions, and this is not recapitulated by more traditional 2D models. Microfluidics has been used to design 3D tissue models that allow for intricate arrangements of cells and extracellular spaces, thus allowing for more physiologically relevant in vitro model systems. Here, we summarize the multitude of microfluidic devices designed to study the immune system with the ultimate goal to improve existing and design new immunotherapies. We have included models of the different immune organs, including bone marrow and lymph node (LN), models of immunity in diseases such as cancer and inflammatory bowel disease, and therapeutic models to test or engineer new immune-modulatory treatments. We particularly emphasize research on how microfluidic devices are used to better understand different physiological states and how interactions within the immune microenvironment can influence the efficacy of immunotherapies.

Indexed as

MicrofluidicsNeoplasmsHumansImmunotherapyLab-On-A-Chip DevicesTumor MicroenvironmentBiological barriersDevicesDiseaseIn vitroModel systems

Identifiers

PMID34215998
PMCPMC9059778

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.